샘플 요청 목록

 카트 문의
시장보고서
상품코드
1777480

세계의 원발성 면역결핍증 시장

Primary Immunodeficiency Disorders
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 280 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

원발성 면역결핍증 세계 시장은 2030년까지 104억 달러에 달할 전망

2024년에 79억 달러로 추정되는 원발성 면역결핍증 세계 시장은 분석 기간인 2024-2030년에 CAGR 4.8%로 성장하여 2030년에는 104억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 면역글로불린 보충 요법은 CAGR 3.8%를 기록하며 분석 기간 종료시에는 44억 달러에 달할 것으로 예측됩니다. 항생제 요법 부문의 성장률은 분석 기간 동안 CAGR 4.9%로 추정됩니다.

미국 시장은 21억 달러로 추정, 중국은 CAGR 7.5%로 성장 예측

미국의 원발성 면역결핍증 시장은 2024년에 21억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2024년부터 2030년 분석 기간 동안 CAGR 7.5%로 성장하여 2030년까지 20억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.4%와 4.8%로 예측됩니다. 유럽에서는 독일이 CAGR 3.1%로 성장할 것으로 예측됩니다.

세계 원발성 면역결핍증(PID) 시장 - 주요 동향 및 촉진요인 정리

원발성 면역결핍증 치료에 대한 수요가 증가하는 이유는 무엇일까?

원발성 면역결핍증(PID)은 감염에 대한 면역체계의 방어능력을 떨어뜨려 재발성 중증 질환에 취약하게 만드는 희귀 유전질환군입니다. 450개 이상의 PID 병형이 확인되었으며, 효과적인 진단 도구와 치료법에 대한 수요가 크게 증가하고 있습니다. 유전자 검사와 신생아 선별검사 프로그램의 발전으로 조기 발견이 향상되어 심각한 합병증을 예방할 수 있는 적시에 개입할 수 있게 되었습니다. PID의 치료법에는 주로 면역글로불린 대체요법(IVIG 및 SCIG), 조혈모세포 이식(HSCT), 유전자 치료 등이 있습니다. 또한, 면역부전의 근본적인 분자 기전이 밝혀지면서 표적 생물학적 제제 및 면역 조절 요법이 개발되어 보다 개인화된 치료 옵션이 제공되고 있습니다. 또한, 희귀질환 연구에 대한 환자들의 지지와 자금 지원이 증가함에 따라 치료 접근성을 개선하고 치료 파이프라인을 확장하기 위한 노력이 가속화되고 있습니다. 의료 서비스 제공자와 정책 입안자들이 PID 관리를 우선시하는 가운데, 진단 및 치료 솔루션 시장은 크게 성장할 것으로 예상됩니다.

PID 치료의 진전을 가로막는 과제는 무엇인가?

PID의 진단과 치료법이 발전하고 있음에도 불구하고, 이 분야에 대한 접근과 혁신을 제한하는 몇 가지 과제가 있습니다. 주요 관심사 중 하나는 많은 PID 환자들에게 평생 동안 필요한 면역글로불린 대체 요법에 대한 높은 비용입니다. IVIG 제조를 위한 기증자 혈장의 가용성이 제한되어 있어 공급이 더욱 제한되어 주기적인 공급 부족과 가격 변동이 발생하고 있습니다. 또한, 많은 증상이 일반적인 감염이나 자가면역질환과 중복되는 경우가 많아 진단이 늦어지거나 놓칠 수 있습니다. 또한, 규제 장벽은 새로운 유전자 치료제 및 생물학적 제제의 승인을 지연시키고, 새로운 치료법의 시장 출시까지 걸리는 시간을 연장시키고 있습니다. 또한, 의료 인프라와 진단 능력의 격차는 저소득 지역에서 PID 치료에 대한 적시 접근을 방해하고, 의료 서비스를 제대로 받지 못하는 사람들의 질병 부담을 악화시키고 있습니다. 이러한 문제를 해결하기 위해서는 대체 치료법에 대한 투자를 늘리고, 신생아 선별검사 프로그램을 확대하며, 접근성과 경제적 부담을 개선하기 위해 이해관계자 간의 협력을 강화해야 합니다.

유전자 치료와 면역 치료의 혁신은 PID 치료에 어떤 변화를 가져오고 있는가?

유전자 치료와 면역 조절 치료의 기술 발전은 PID 치료의 전망을 바꾸고 있으며, 근본적이고 표적화된 치료 접근법을 제공하고 있습니다. 유전자 치료는 중증복합면역결핍증(SCID) 및 만성 육아종성 질환(CGD)과 같은 중증 PID를 유발하는 근본적인 유전자 돌연변이를 교정하고, 평생 IVIG 치료의 필요성을 감소시키는 유망한 결과를 보여주고 있습니다. 단클론항체 및 사이토카인 기반 치료법의 개발은 치료 옵션을 더욱 넓히고 특정 면역 결핍 아형을 가진 환자의 면역 기능을 조절하는 데 도움을 주고 있습니다. 또한, 정밀의료의 발전으로 환자의 계층화가 진행되어 유전자 프로파일에 따라 가장 효과적인 치료를 받을 수 있는 환자 계층화가 이루어지고 있습니다. AI 기반 진단 도구와 차세대 염기서열 분석기(NGS)는 조기 발견과 위험 평가를 개선하고 적극적인 치료 계획을 촉진하고 있습니다. 원격의료와 디지털 환자 모니터링의 통합은 질병 관리를 강화하고, 의료 서비스 제공자가 치료에 대한 환자의 반응을 실시간으로 추적할 수 있도록 돕습니다. 이러한 기술 혁신이 진행됨에 따라 PID 치료의 미래는 점점 더 개인화되고 효과적이 될 것입니다.

원발성 면역결핍증 시장의 성장 원동력은?

원발성 면역결핍증 시장의 성장은 희귀 면역 질환에 대한 인식 증가, 유전자 진단의 발전, 치료 옵션의 확대 등 여러 요인에 의해 주도되고 있습니다. 스크리닝 프로그램의 개선으로 PID로 진단되는 유병률이 증가함에 따라 면역글로불린 요법 및 표적 생물학적 제제에 대한 수요 확대에 기여하고 있습니다. 희귀질환 연구와 희귀질환 치료제 개발을 지원하는 정부 이니셔티브는 시장 확대를 더욱 가속화하고 제약회사들이 새로운 치료법에 대한 투자를 촉진하고 있습니다. 또한, 세포 치료와 유전자 치료의 채택이 확대되고 있는 것도 PID 치료의 전망을 크게 바꾸고 있으며, 중증 사례에 대한 근본적인 해결책을 제공할 수 있습니다. 또한, 환자 지원 단체와 비영리 단체는 연구 자금 지원, 진단 서비스 접근성 강화, 질병 인식 개선에 중요한 역할을 하고 있습니다. 치료의 혁신과 세계 헬스케어 정책이 계속 발전함에 따라, 원발성 면역결핍증 시장은 보다 효과적이고 접근하기 쉬운 치료 솔루션의 길을 열어주며 큰 성장이 예상됩니다.

부문

치료 유형(면역글로불린 보충 요법, 항생제 요법, 줄기세포/골수 이식, 유전자 치료, 기타 치료 유형), 질환 유형(항체 결핍증, 세포성 면역결핍증, 자연 면역질환, 기타 질환 유형)

조사 대상 기업 사례

  • Abbott Laboratories
  • ADMA Biologics
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Baxter International Inc.
  • Bio Products Laboratory Ltd.
  • Biotest AG
  • CSL Behring LLC
  • GC Biopharma
  • Grifols S.A.
  • Horizon Therapeutics plc
  • Kedrion Biopharma Inc.
  • LFB S.A.
  • Lupin Pharmaceuticals
  • Merck KGaA
  • Novartis International AG
  • Octapharma AG
  • Pharming Group N.V.
  • Takeda Pharmaceutical Company Limited

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.05

Global Primary Immunodeficiency Disorders Market to Reach US$10.4 Billion by 2030

The global market for Primary Immunodeficiency Disorders estimated at US$7.9 Billion in the year 2024, is expected to reach US$10.4 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Immunoglobulin Replacement Therapy, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the Antibiotic Therapy segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.1 Billion While China is Forecast to Grow at 7.5% CAGR

The Primary Immunodeficiency Disorders market in the U.S. is estimated at US$2.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Primary Immunodeficiency Disorders (PID) Market - Key Trends & Drivers Summarized

Why Is There an Increasing Need for Primary Immunodeficiency Disorder Treatments?

Primary Immunodeficiency Disorders (PIDs) are a group of rare genetic conditions that impair the immune system’s ability to defend against infections, making affected individuals highly susceptible to recurrent and severe illnesses. With over 450 identified forms of PID, the demand for effective diagnostic tools and therapeutic solutions has risen significantly. Advances in genetic testing and newborn screening programs have improved early detection, enabling timely interventions that prevent severe complications. Treatment options for PIDs primarily include immunoglobulin replacement therapy (IVIG and SCIG), hematopoietic stem cell transplantation (HSCT), and gene therapy. The growing understanding of the molecular mechanisms underlying immunodeficiencies has also led to the development of targeted biologics and immunomodulatory therapies, offering more personalized treatment options. Additionally, increased patient advocacy and funding for rare disease research have accelerated efforts to enhance treatment accessibility and expand therapeutic pipelines. As healthcare providers and policymakers prioritize PID management, the market for diagnostic and therapeutic solutions is poised for significant growth.

What Challenges Are Hindering the Advancement of PID Therapies?

Despite advancements in PID diagnosis and treatment, several challenges continue to limit access and innovation in the field. One of the primary concerns is the high cost of immunoglobulin replacement therapy, which is a lifelong requirement for many PID patients. The limited availability of donor plasma for IVIG production further constrains supply, leading to periodic shortages and pricing fluctuations. Additionally, the complexity of diagnosing PIDs presents a significant hurdle, as many symptoms overlap with common infections or autoimmune diseases, resulting in delayed or missed diagnoses. Regulatory barriers also slow down the approval of emerging gene therapies and biologics, prolonging the time-to-market for new treatments. Furthermore, disparities in healthcare infrastructure and diagnostic capabilities prevent timely access to PID therapies in low-income regions, exacerbating disease burden in underserved populations. Addressing these challenges requires increased investment in alternative treatment approaches, expanded newborn screening programs, and greater collaboration between stakeholders to improve access and affordability.

How Are Innovations in Gene Therapy and Immunotherapy Transforming PID Treatment?

Technological advancements in gene therapy and immunomodulatory treatments are reshaping the landscape of PID management, offering curative and targeted therapeutic approaches. Gene therapy has shown promising results in correcting underlying genetic mutations responsible for severe PIDs, such as Severe Combined Immunodeficiency (SCID) and Chronic Granulomatous Disease (CGD), reducing the need for lifelong IVIG therapy. The development of monoclonal antibodies and cytokine-based therapies is further expanding treatment options, helping to regulate immune function in patients with specific immunodeficiency subtypes. Additionally, advancements in precision medicine are enabling better patient stratification, ensuring that individuals receive the most effective therapy based on their genetic profile. AI-driven diagnostic tools and next-generation sequencing (NGS) are improving early detection and risk assessment, facilitating proactive treatment planning. The integration of telehealth and digital patient monitoring is also enhancing disease management, allowing healthcare providers to track patient responses to treatment in real time. As these innovations continue to progress, the future of PID treatment is becoming increasingly personalized and effective.

What Is Driving the Growth of the Primary Immunodeficiency Disorders Market?

The growth in the primary immunodeficiency disorders market is driven by several factors, including increasing awareness of rare immune disorders, advancements in genetic diagnostics, and expanding treatment options. The rising prevalence of diagnosed PID cases, facilitated by improved screening programs, is contributing to higher demand for immunoglobulin therapy and targeted biologics. Government initiatives supporting rare disease research and orphan drug development are further accelerating market expansion, encouraging pharmaceutical companies to invest in novel therapies. The growing adoption of cell and gene therapy approaches is also reshaping the PID treatment landscape, offering potentially curative solutions for severe cases. Additionally, patient advocacy organizations and non-profit initiatives are playing a key role in driving research funding, enhancing access to diagnostic services, and improving disease awareness. As treatment innovations and global healthcare policies continue to evolve, the primary immunodeficiency disorders market is expected to see substantial growth, paving the way for more effective and accessible care solutions.

SCOPE OF STUDY:

The report analyzes the Primary Immunodeficiency Disorders market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy, Other Treatment Types); Disease Type (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, Other Disease Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott Laboratories
  • ADMA Biologics
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Baxter International Inc.
  • Bio Products Laboratory Ltd.
  • Biotest AG
  • CSL Behring LLC
  • GC Biopharma
  • Grifols S.A.
  • Horizon Therapeutics plc
  • Kedrion Biopharma Inc.
  • LFB S.A.
  • Lupin Pharmaceuticals
  • Merck KGaA
  • Novartis International AG
  • Octapharma AG
  • Pharming Group N.V.
  • Takeda Pharmaceutical Company Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Primary Immunodeficiency Disorders - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence and Improved Diagnosis of Rare Immunodeficiencies Throws the Spotlight on Market Expansion Opportunities
    • Growth in Newborn Screening Programs and Early Detection Initiatives Drives Adoption of Life-Saving Therapies for PIDs
    • Advancements in Genetic Testing and Next-Generation Sequencing Expand Addressable Market Through Precise Diagnosis
    • Increased Availability of Immunoglobulin Replacement Therapies Drives Adoption of Long-Term Disease Management Strategies
    • Emergence of Subcutaneous Immunoglobulin (SCIG) Products Strengthens Business Case for Home-Based Treatment Modalities
    • Surge in Research on Monogenic Immune Disorders Spurs Growth in Targeted Therapeutic Development
    • Expansion of Orphan Drug Designation and Regulatory Incentives Propels Investment in Novel PID Treatments
    • Rising Use of Hematopoietic Stem Cell Transplantation (HSCT) in Severe PID Cases Enhances Treatment Landscape Complexity
    • Integration of Gene Therapy Platforms Generates Breakthrough Opportunities in Curative PID Interventions
    • Improved Physician Awareness and Educational Outreach Drives Early Intervention and Therapy Uptake
    • Increasing Support from Patient Advocacy Organizations Accelerates Public Policy Engagement and Access to Therapies
    • Development of Long-Acting Immunoglobulin Formulations Drives Convenience-Oriented Innovation in PID Care
    • Expansion of Specialty Pharmacies and Infusion Centers Strengthens Supply Chain for Advanced PID Treatments
    • Growing Application of Personalized Medicine Approaches Spurs Customized Immunomodulatory Therapies
    • Adoption of AI-Driven Clinical Decision Support Tools Enhances Diagnostic Accuracy and Treatment Optimization
    • Rising Government and Non-Profit Funding for Rare Disease Research Generates Pipeline Momentum
    • Emergence of Combination Immunotherapy Strategies Drives Clinical Trials in Complex Immune Dysregulation Disorders
    • Challenges in Reimbursement and Treatment Cost Justification Create Demand for Health-Economic Evidence
    • Globalization of Clinical Trials Expands Therapeutic Availability and Regional Market Penetration
    • Focus on Pediatric Patient-Centric Formulations and Administration Routes Enhances Compliance and Treatment Outcomes
    • Digital Health Integration in PID Patient Monitoring and Adherence Management Sustains Market Growth
    • Post-COVID Emphasis on Immune Health Drives Increased Vigilance and Screening for Underlying Immune Deficiencies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Primary Immunodeficiency Disorders Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Primary Immunodeficiency Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Primary Immunodeficiency Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Immunoglobulin Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Immunoglobulin Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Immunoglobulin Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antibiotic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antibiotic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Antibiotic Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Stem Cell / Bone Marrow Transplantation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Stem Cell / Bone Marrow Transplantation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Stem Cell / Bone Marrow Transplantation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Antibody Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Antibody Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Antibody Deficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cellular Immunodeficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cellular Immunodeficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Cellular Immunodeficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Innate Immune Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Innate Immune Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Innate Immune Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • CHINA
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Primary Immunodeficiency Disorders by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Primary Immunodeficiency Disorders by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • FRANCE
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Primary Immunodeficiency Disorders by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Primary Immunodeficiency Disorders by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • INDIA
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Primary Immunodeficiency Disorders by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Primary Immunodeficiency Disorders by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Primary Immunodeficiency Disorders by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Primary Immunodeficiency Disorders by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030
  • AFRICA
    • Primary Immunodeficiency Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Primary Immunodeficiency Disorders by Treatment Type - Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Primary Immunodeficiency Disorders by Treatment Type - Percentage Breakdown of Value Sales for Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem Cell / Bone Marrow Transplantation, Gene Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Primary Immunodeficiency Disorders by Disease Type - Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Primary Immunodeficiency Disorders by Disease Type - Percentage Breakdown of Value Sales for Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders and Other Disease Types for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제